HomeNewsApi business

Api Business

Jump to

Nectar Lifesciences shares down 13 percent as it sells core API and formulation division for Rs 1,290 crore

Nectar Life has been attempting to streamline its operations and strengthen its financial position in order to unlock shareholder value.
Core generics, API biz to drive FY16 growth: Dr Reddy's

GV Prasad, Co-Chairman & CEO of Dr Reddy‘s Laboratories said a lot of growth is seen in emerging markets
Expect double-digit growth in FY15: Nectar Life

In an interview to CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences details the Q1 performance of the company and what he expects in the future.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Api Business

Nectar Lifesciences shares down 13 percent as it sells core API and formulation division for Rs 1,290 crore

Core generics, API biz to drive FY16 growth: Dr Reddy's

Expect double-digit growth in FY15: Nectar Life